{"id":"NCT03102762","sponsor":"Cairo University","briefTitle":"Botulinum Toxin for Erectile Dysfunction","officialTitle":"Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Erectile Dysfunction (Phase 2 Study)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-01-03","primaryCompletion":"2019-01-10","completion":"2019-01-10","firstPosted":"2017-04-06","resultsPosted":"2019-12-05","lastUpdate":"2020-01-07"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sexual Dysfunction","Erectile Dysfunction"],"interventions":[{"type":"DRUG","name":"Botulinum Toxin Type A","otherNames":[]},{"type":"DRUG","name":"Normal saline","otherNames":[]}],"arms":[{"label":"Botulinum Toxin Type A (BTX-A) Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of intra-cavernosal Botulinum toxin injection as an alternative line of treatment in patients with erectile dysfunction - not responding to oral PDE5i - through cavernosal smooth muscle relaxation.","primaryOutcome":{"measure":"Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment","timeFrame":"Baseline","effectByArm":[{"arm":"BTX-A Group","deltaMin":34.52,"sd":12.15},{"arm":"Placebo Group","deltaMin":30.85,"sd":15.26}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Egypt"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.gov/ct2/show/record/NCT02584686"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":[]}}